Abstracts tagged "C Reactive Protein"

Abstract Number: 405 • 2014 ACR/ARHP Annual Meeting
14-3-3η: A Mechanistic Biomarker That Supports the Concept of “Uncoupling” of Inflammation and Joint Damage
Dirkjan van Schaardenburg¹, Mairead Murphy², Yuan Gui², Samina Turk³, Walter P. Maksymowych⁴, Kelly Young⁵ and Anthony Marotta⁶, ¹Dr Jan van Breemenstraat 2, Reade, Amsterdam, Netherlands, ²Augurex Life Sciences Corp., North Vancouver, BC, Canada, ³Reade, Amsterdam, Netherlands, ⁴Medicine, University of Alberta, Edmonton, AB, Canada, ⁵Rheumatoid Patient Foundation, Cocoa, FL, ⁶1423 Dempsey Road, Augurex Life Sciences Corp., North Vancouver, BC, Canada
Background/Purpose In RA, irreversible joint damage often begins within the first year of symptom onset. A compelling and growing body of data describing the "uncoupling"…
Abstract Number: 152 • 2014 ACR/ARHP Annual Meeting
Subclinical Synovial Inflammation in Gout
Priya Chowalloor^1,2, Patrick Cheah³ and Helen I. Keen^1,2, ¹Rheumatology, Royal Perth Hospital, Perth, Australia, ²School of Medicine and Pharmacology, The University of Western Australia, Crawley, Australia, ³Rheumatology, Sir Charles Gairdner Hospital, Nedlands, Australia
Background/Purpose Gout is poorly managed in the community. Long standing poorly controlled gout can lead into progressive destructive arthropathy, decreased quality of life and increased…
Abstract Number: 2674 • 2013 ACR/ARHP Annual Meeting
Vitamin D Deficiency Is Common and Associated With Increased C-Reactive Protein In Children With Lupus: An Atherosclerosis Prevention In Pediatric Lupus Erythematosus Substudy
Angela B. Robinson¹, Vin Tangpricha², Eric Yow³, Reut Gurion⁴, Grace McComsey⁴ and Laura E. Schanberg⁵, ¹Pediatric Infectious Disease, Rheumatology and Geographic Medicine, Rainbow Babies and Children's Hospital / Case Medical Center, Cleveland, OH, ²Medicine, Emory University School of Medicine, Atlanta, GA, ³Biostatistics, Duke Clinical Research Institute, Durham, NC, ⁴Pediatric Infectious Diseases, Rheumatology, and Geographic Medicine, Rainbow Babies and Children's Hospital / Case Medical Center, Cleveland, OH, ⁵Pediatrics, Duke University Medical Center, Durham, NC
Background/Purpose: Epidemiologic associations suggest vitamin D may play a role in inflammation and progression of atherosclerosis. Using frozen serum, carotid intima medial thickness (CIMT) measurements,…
Abstract Number: 2415 • 2013 ACR/ARHP Annual Meeting
Phosphorylated Venous Endothelial Nitric Oxide Synthase Is Elevated In Rheumatoid Arthritis Subjects With High Disease Activity
Elizabeth Blair Solow¹, Wanpen Vongpatanasin² and David R. Karp³, ¹Rheumatology, UT Southwestern Medical Center, Dallas, TX, ²Cardiology, UT Southwestern Medical Center, Dallas, TX, ³Rheumatic Diseases Division, UT Southwestern Medical Center, Dallas, TX
Background/Purpose: Endothelial dysfunction is present in arthritis animal models and rheumatoid arthritis (RA), a population known to develop premature cardiovascular disease. Previous studies indicate inflammation…
Abstract Number: 1274 • 2013 ACR/ARHP Annual Meeting
Maternal Vitamin D, Fetal C-Reactive Protein and Brain Natriuretic Peptide Associate With The Development and Morbidity Of Cardiac Neonatal Lupus
Amit Saxena¹, Peter M. Izmirly², Joanne H. Reed³, Sara Sahl², Deborah Friedman⁴, Robert M. Clancy³ and Jill P. Buyon², ¹Rheumatology, New York University School of Medicine, New York, NY, ²Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ³Medicine, New York University School of Medicine, New York, NY, ⁴Division of Pediatric Cardiology, New York Medical College, Valhalla, NY
Background/Purpose: Women with anti-Ro antibodies face the risk of having a child with cardiac Neonatal Lupus (NL), characterized by congenital heart block and/or cardiomyopathy. Biomarkers…
Abstract Number: 375 • 2013 ACR/ARHP Annual Meeting
Systemic Inflammation Contributes To Depression In Patients With Rheumatoid Arthritis
Mary Margaretten¹, Laura Trupin², Patricia P. Katz², Gabriela Schmajuk², Jinoos Yazdany², Chris Tonner², Jennifer Barton² and Edward H. Yelin³, ¹Rheumatology, University of California, San Francisco, San Francisco, CA, ²Medicine, University of California, San Francisco, San Francisco, CA, ³Arthritis Research Group, University of California, San Francisco, San Francisco, CA
Background/Purpose: Prior research suggests that systemic inflammation contributes to the pathogenesis of depression, but longitudinal studies in patients with rheumatoid arthritis (RA) are lacking. Comorbid…
Abstract Number: 1374 • 2012 ACR/ARHP Annual Meeting
Value of C-Reactive Protein Level At Diagnosis of Psoriatic Arthritis in Predicting the Future Need for Treatment with Tumor Necrosis Factor-á Inhibitors
Yair Molad¹ and Shachaf Ofer-Shiber², ¹Rheumatology Unit, Beilinson Hospital, Rabin Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Petach-Tikva, Israel, ²Internal Medicine H, Beilinson Hospital, Rabin Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Petah Tikva, Israel
Background/Purpose: To determine the value of acute-phase reactant levels at diagnosis of psoriatic arthritis in predicting the risk of failure of conventional treatment with disease-modifying…
Abstract Number: 1325 • 2012 ACR/ARHP Annual Meeting
Prevention of Joint Destruction in Patients with High Disease Activity or High C-Reactive Protein
Yoshiya Tanaka¹, Masayoshi Harigai², Tsutomu Takeuchi³, Hisashi Yamanaka⁴, Naoki Ishiguro⁵, Kazuhiko Yamamoto⁶, Yutaka Ishii⁷, Daniel Baker⁸, Nobuyuki Miyasaka⁹ and Takao Koike¹⁰, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²Dept of Pharmacovigilance, Tokyo Medical and Dental University, Tokyo, Japan, ³Keio University School of Medicine, Tokyo, Japan, ⁴Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ⁵Department of Orthopedic Surgery, Nagoya University, Graduate School & Faculty of Medicine, Nagoya, Aichi, Japan, ⁶Department of Allergy & Rheumatology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan, ⁷Medical Affaires, Janssen Pharmaceutical K.K, Tokyo, Japan, ⁸Janssen Research & Development, LLC., Spring House, PA, ⁹Department of Medicine and Rheumatology and Global Center of Excellence Program, Tokyo Medical and Dental University, Tokyo, Japan, ¹⁰Sapporo medical center NTT EC, Sapporo, Japan
Prevention of Joint Destruction in Patients with High Disease Activity or High C-reactive proteinBackground/Purpose: In Japan, 2 doses (50mg and 100mg) of golimumab (GLM) were…
Abstract Number: 591 • 2012 ACR/ARHP Annual Meeting
Structural Progression of Ankylosing Spondylitis Associated with Elevation in Two NOVEL, Inflammatory Biomarkers; Matrix Metalloproteinase and Cathepsin-Derived
Anne C. Bay-Jensen¹, Morten Asser Karsdal², Stephanie Wichuk³, Zheng Zhao⁴, Robert GW Lambert⁵, Per Qvist⁶ and Walter P. Maksymowych⁷, ¹Cartilage Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, ²Nordic Bioscience A/S, Herlev, Denmark, ³Medicine, University of Alberta, Edmonton, AB, Canada, ⁴Department of Rheumatology, University of Alberta and PLA General Hospital, Beijing, PR China, Beijing, AB, China, ⁵Radiology, University of Alberta, Edmonton, AB, Canada, ⁶Nordic Bioscience, Herlev, Denmark, ⁷Department of Medicine, University of Alberta, Edmonton, AB, Canada
Background/Purpose: Current inflammatory biomarkers, such as CRP, have insufficient sensitivity and specificity to be broadly accepted for diagnosis and prognosis of AS. We hypothesized, that…
Abstract Number: 362 • 2012 ACR/ARHP Annual Meeting
Response to Etanercept, but Not Infliximab or Adalimumab, Is Inversely Associated with Body Mass Index
James R. Maxwell¹, Darren Plant², Anne Barton², Kimme L. Hyrich³, Ann W. Morgan⁴, John Isaacs⁵ and Anthony G. Wilson⁶, ¹Infection & Immunity, University of Sheffield, Sheffield, United Kingdom, ²Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom, ³Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom, ⁴Section of Musculoskeletal Disease, NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Molecular Medicine, University of Leeds, Leeds, United Kingdom, ⁵Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom, ⁶Infection and Immunity, University of Sheffield, Sheffield, United Kingdom
Background/Purpose: Recent studies have demonstrated inverse association between BMI and radiographic severity in patients with Rheumatoid Arthritis (RA). There is also preliminary evidence that body…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].